New generation anti-B cell therapy

Project 16

Project leader:

Prof. Dr. med. Thomas Dörner

CharitéUniversitätsmedizin Berlin

CCM: Campus Charité Mitte

Medizinische Klinik m. S. Rheumatologie und Klinische Immunologie

Postal address:

Charitéplatz 1

10117 Berlin

t: +49 30 450 52524

f: +49 30 450 525941

Links:

Summary

Successful translation has brought the non-B cell depleting anti-CD22 antibody (epratuzumab) in trilas of SLE. The project will delineate its mechanism of action by exploring CD22 downstream intracellular pathways (BCR-independent and -dependent) on kinase phosphorylation profiles, intracellular Ca2+ flux, mRNA expression, and intracellular cytokine production. Patients will also be monitored under this therapy. The extracellular role of CD22 as sialoadhesin adhesion molecule and its role as homing receptor for different lymphoid organs will be studied as potential approach of competition. Finally, an innovative bispecific anti-CD22/CD74 antibody targeting B cells and monocytes will be throroughly investigated pre-clinically.

Research Database

For more details please use the Charité undefinedresearch database.